Brainstorm Cell Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Brainstorm Cell Therapeutics

30/03/2023 14:31

* Brainstorm Cell Therapeutics Inc  BCLI.OQ  reported a
quarterly
adjusted loss of 13 cents​​ per share for the quarter ended in
December. The mean expectation of two analysts for the quarter
was for a loss of 14 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Brainstorm Cell Therapeutics Inc's reported EPS for the
quarter
was a loss of 13 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Brainstorm Cell Therapeutics Inc shares had risen by 48.8%
this
quarter.
    * The company reported a quarterly loss of $5.02 million.
    * Wall Street's median 12-month price target for Brainstorm
Cell
Therapeutics Inc is $12.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 30 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.14          -0.13          Beat
 Sep. 30 2022      -0.18          -0.19          Missed
 Jun. 30 2022      -0.15          -0.19          Missed
 Mar. 31 2022      -0.13          -0.15          Missed